MA41778A - Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine - Google Patents
Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaineInfo
- Publication number
- MA41778A MA41778A MA041778A MA41778A MA41778A MA 41778 A MA41778 A MA 41778A MA 041778 A MA041778 A MA 041778A MA 41778 A MA41778 A MA 41778A MA 41778 A MA41778 A MA 41778A
- Authority
- MA
- Morocco
- Prior art keywords
- benzimidazole derivatives
- bromodomain inhibitors
- compounds
- formula
- salts
- Prior art date
Links
- 102000001805 Bromodomains Human genes 0.000 title abstract 2
- 108050009021 Bromodomains Proteins 0.000 title abstract 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
Composés de formule (i) et leurs sels: dans lesquels r1, r2, r3, r4 sont définis ici. Les composés de formule (i) et leurs sels inhibent la liaison de la famille bet des protéines de bromodomaïne à, par exemple, des résidus de lysine acétylés et peuvent donc être utilisés en thérapie, par exemple dans le traitement de maladies auto-immunes et inflammatoires, comme la polyarthrite rhumatoïde; et les cancers.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504689.9A GB201504689D0 (en) | 2015-03-19 | 2015-03-19 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41778A true MA41778A (fr) | 2018-01-24 |
Family
ID=53052091
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046981A MA46981A (fr) | 2015-03-19 | 2016-03-17 | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine |
| MA041778A MA41778A (fr) | 2015-03-19 | 2016-03-17 | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046981A MA46981A (fr) | 2015-03-19 | 2016-03-17 | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US10442786B2 (fr) |
| EP (2) | EP3549939A1 (fr) |
| JP (1) | JP6419990B2 (fr) |
| KR (1) | KR102072850B1 (fr) |
| CN (1) | CN107635989B (fr) |
| AR (1) | AR103934A1 (fr) |
| AU (1) | AU2016232217B2 (fr) |
| BR (1) | BR112017019779B1 (fr) |
| CA (1) | CA2979504C (fr) |
| CL (1) | CL2017002332A1 (fr) |
| CO (1) | CO2017009992A2 (fr) |
| CR (1) | CR20170430A (fr) |
| CY (1) | CY1121855T1 (fr) |
| DK (1) | DK3271349T3 (fr) |
| DO (1) | DOP2017000213A (fr) |
| EA (1) | EA033594B1 (fr) |
| ES (1) | ES2735417T3 (fr) |
| GB (1) | GB201504689D0 (fr) |
| HR (1) | HRP20191186T1 (fr) |
| HU (1) | HUE044414T2 (fr) |
| IL (1) | IL254318B (fr) |
| LT (1) | LT3271349T (fr) |
| MA (2) | MA46981A (fr) |
| ME (1) | ME03485B (fr) |
| MX (1) | MX2017012023A (fr) |
| PE (1) | PE20180032A1 (fr) |
| PH (1) | PH12017501620A1 (fr) |
| PL (1) | PL3271349T3 (fr) |
| PT (1) | PT3271349T (fr) |
| RS (1) | RS59056B1 (fr) |
| SG (1) | SG11201707356QA (fr) |
| SI (1) | SI3271349T1 (fr) |
| SM (1) | SMT201900428T1 (fr) |
| TW (1) | TW201706257A (fr) |
| UY (1) | UY36589A (fr) |
| WO (1) | WO2016146738A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| HK1256753A1 (zh) | 2015-08-11 | 2019-10-04 | Neomed Institute | 芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途 |
| US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| CN114605387A (zh) | 2015-08-12 | 2022-06-10 | 埃皮吉纳提克斯股份有限公司 | 取代的苯并咪唑、它们的制备和它们作为药物的用途 |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
| WO2017127930A1 (fr) | 2016-01-28 | 2017-08-03 | Neomed Institute | [1,2,4]triazolo[4,3-a]pyridines substituées, leur préparation et leur utilisation comme médicaments |
| GB201614940D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
| GB201614939D0 (en) | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
| GB201614934D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
| US10617680B2 (en) * | 2017-04-18 | 2020-04-14 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| CN109280046B (zh) * | 2017-07-21 | 2021-02-02 | 浙江海正药业股份有限公司 | 苯并咪唑类衍生物及其制备方法及其在医药上的用途 |
| WO2019154329A1 (fr) * | 2018-02-06 | 2019-08-15 | 上海海和药物研究开发有限公司 | Composé présentant une activité inhibitrice de bet, son procédé de préparation et son utilisation |
| CN109369432B (zh) * | 2018-11-02 | 2021-06-25 | 永农生物科学有限公司 | (s)-4-氯-2-氨基丁酸酯的制备方法 |
| JP2022053557A (ja) * | 2019-02-08 | 2022-04-06 | マルホ株式会社 | ピリドン誘導体 |
| EP3937936A4 (fr) * | 2019-03-15 | 2022-12-28 | Forma Therapeutics, Inc. | Inhibition de la protéine de liaison à un élément sensible à l'amp cyclique (creb) |
| WO2020219168A1 (fr) * | 2019-04-24 | 2020-10-29 | Convergene, Llc | Inhibiteurs de bromodomaines à petites molécules et leurs utilisations |
| WO2020223370A1 (fr) * | 2019-04-29 | 2020-11-05 | The Board Of Regents Of The University Of Texas System | Compositions et méthodes de traitement d'infections à schistosomes |
| CN116217416A (zh) * | 2022-12-31 | 2023-06-06 | 黄淮学院 | 一种苯并咪唑类药物中间体3-硝基-4-乙基氨基苯甲醇的制备方法 |
| IL324913A (en) * | 2023-05-30 | 2026-01-01 | 16380026 Canada Inc | Cyp26b1 inhibitor compounds and methods of use thereof |
| CN119219631B (zh) * | 2024-12-04 | 2025-04-18 | 山东大学 | 一种bet蛋白溴结构域bd1选择性共价抑制剂及其制备方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
| ATE478067T1 (de) | 2006-03-31 | 2010-09-15 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors |
| EP2493310A4 (fr) * | 2009-10-27 | 2014-03-12 | Glaxosmithkline Llc | Benzimidazoles utilisés en tant qu'inhibiteurs de l'acide gras synthase |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| KR101594002B1 (ko) | 2010-10-06 | 2016-02-15 | 글락소스미스클라인 엘엘씨 | Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체 |
| GB201114103D0 (en) * | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (fr) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Inhibiteurs de bromodomaine |
| JP2016507496A (ja) * | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| CN105073747B (zh) | 2013-03-15 | 2017-06-06 | 普莱希科公司 | 杂环化合物及其应用 |
| TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類 |
| TWI527811B (zh) * | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| CN105473581B (zh) * | 2013-06-21 | 2019-04-23 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
| US20150051208A1 (en) * | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| US9428515B2 (en) * | 2014-05-09 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazole derivatives |
| GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201504694D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
-
2015
- 2015-03-19 GB GBGB1504689.9A patent/GB201504689D0/en not_active Ceased
-
2016
- 2016-03-15 AR ARP160100683A patent/AR103934A1/es unknown
- 2016-03-17 BR BR112017019779-0A patent/BR112017019779B1/pt not_active IP Right Cessation
- 2016-03-17 LT LTEP16710214.4T patent/LT3271349T/lt unknown
- 2016-03-17 PL PL16710214T patent/PL3271349T3/pl unknown
- 2016-03-17 CN CN201680027314.8A patent/CN107635989B/zh not_active Expired - Fee Related
- 2016-03-17 JP JP2017548404A patent/JP6419990B2/ja not_active Expired - Fee Related
- 2016-03-17 KR KR1020177030073A patent/KR102072850B1/ko not_active Expired - Fee Related
- 2016-03-17 MX MX2017012023A patent/MX2017012023A/es unknown
- 2016-03-17 SI SI201630321T patent/SI3271349T1/sl unknown
- 2016-03-17 EP EP19174047.1A patent/EP3549939A1/fr not_active Withdrawn
- 2016-03-17 MA MA046981A patent/MA46981A/fr unknown
- 2016-03-17 RS RS20190986A patent/RS59056B1/sr unknown
- 2016-03-17 CR CR20170430A patent/CR20170430A/es unknown
- 2016-03-17 HU HUE16710214 patent/HUE044414T2/hu unknown
- 2016-03-17 AU AU2016232217A patent/AU2016232217B2/en not_active Ceased
- 2016-03-17 ME MEP-2019-171A patent/ME03485B/fr unknown
- 2016-03-17 SG SG11201707356QA patent/SG11201707356QA/en unknown
- 2016-03-17 EA EA201791973A patent/EA033594B1/ru not_active IP Right Cessation
- 2016-03-17 TW TW105108340A patent/TW201706257A/zh unknown
- 2016-03-17 PT PT16710214T patent/PT3271349T/pt unknown
- 2016-03-17 EP EP16710214.4A patent/EP3271349B1/fr active Active
- 2016-03-17 MA MA041778A patent/MA41778A/fr unknown
- 2016-03-17 US US15/559,556 patent/US10442786B2/en active Active
- 2016-03-17 SM SM20190428T patent/SMT201900428T1/it unknown
- 2016-03-17 UY UY0001036589A patent/UY36589A/es not_active Application Discontinuation
- 2016-03-17 PE PE2017001543A patent/PE20180032A1/es unknown
- 2016-03-17 HR HRP20191186TT patent/HRP20191186T1/hr unknown
- 2016-03-17 WO PCT/EP2016/055792 patent/WO2016146738A1/fr not_active Ceased
- 2016-03-17 DK DK16710214.4T patent/DK3271349T3/da active
- 2016-03-17 ES ES16710214T patent/ES2735417T3/es active Active
- 2016-03-17 CA CA2979504A patent/CA2979504C/fr active Active
-
2017
- 2017-09-04 IL IL254318A patent/IL254318B/en active IP Right Grant
- 2017-09-07 PH PH12017501620A patent/PH12017501620A1/en unknown
- 2017-09-14 CL CL2017002332A patent/CL2017002332A1/es unknown
- 2017-09-19 DO DO2017000213A patent/DOP2017000213A/es unknown
- 2017-09-29 CO CONC2017/0009992A patent/CO2017009992A2/es unknown
-
2019
- 2019-07-26 CY CY20191100796T patent/CY1121855T1/el unknown
- 2019-08-22 US US16/547,909 patent/US11053212B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121855T1 (el) | Παραγωγα βενζιμιδαζολιου ως αναστολεις βρωμοπεδιου | |
| EA202092896A1 (ru) | Гетероциклические и гетероарильные соединения для лечения болезни гентингтона | |
| MA52486B1 (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| EA202092899A1 (ru) | Гетероарильные соединения для лечения болезни гентингтона | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| EA202091508A1 (ru) | 6-азаиндольные соединения | |
| MA64509B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| EA201792047A1 (ru) | Новые соединения | |
| EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA44674A (fr) | Inhibiteurs de bromodomaine | |
| EA201890338A1 (ru) | Оксадиазольные производные, пригодные в качестве ингибиторов hdac | |
| MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| EA201792229A1 (ru) | Ингибиторы бромодомена | |
| EA201790818A1 (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 | |
| MA41238A (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
| EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
| MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| MA39170B1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
| EA201990410A1 (ru) | Производные имидазола и их применение в лечении аутоиммунных или воспалительных заболеваний или раковых заболеваний | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202190452A1 (ru) | Ингибиторы cdk8/19 | |
| EA202190766A1 (ru) | Иммуномодуляторы, их композиции и способы применения |